Uso di farmaci per la prevenzione del tumore al seno
"Our review on use of
medications to reduce risk for primary breast cancer indicated that
tamoxifen and raloxifene reduced the incidence of invasive breast cancer
in women without cancer, but also increased risk for blood clots.
Tamoxifen was more effective than raloxifene in reducing breast cancer,
but also increased the incidence of endometrial cancer and cataracts. Both reduced fractures. Adverse effects were more common in older compared to younger women. Wide-spread
use is limited by the adverse effects of medications and inaccurate
methods to identify candidates. Medications reduce invasive breast
cancer by 7 to 9 cases per 1000 women, assuming 5-years of use. There are 5 per 1000 fewer cases among women using tamoxifen than raloxifene. Estrogen receptor positive breast cancers were reduced, but not estrogen receptor negative"
(Commentary on: Nelson
H et al.: "Use of medications to reduce risk for primary breast cancer:
a systematic review for the u.s. Preventive services task force", Ann Intern Med. 2013 Apr 16;158(8):604-14)